PGIM India Midcap Fund
The scheme seeks to achieve long-term capital appreciation by predominantly investing in equity & equity related instruments of mid cap companies.
Growthvine rating: 1/5 — ranked #30 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹66.93 (as of 2026-11-13) |
|---|
| AUM | ₹10,223 Cr |
|---|
| Expense ratio | 1.49% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Utsav Mehta |
|---|
| Exit load | 0.5% for redemption within 90 days |
|---|
Performance & risk
| 5-year annualised return | 7.48% |
|---|
| Sharpe ratio | 0.29 |
|---|
| Standard deviation | 16.59% |
|---|
| Max drawdown | −38.64% |
|---|
| Alpha | -2.65 |
|---|
| Beta | 0.86 |
|---|
Over 5 years, captured 74.9% of NIFTY Midcap 150's upside and 88.0% of its downside.
Market cap allocation
| Large cap | 18.6% |
|---|
| Mid cap | 68.2% |
|---|
| Small cap | 13.2% |
|---|
Concentration
| Top 5 holdings | 12.5% |
|---|
| Top 10 holdings | 22.9% |
|---|
| Total holdings | 97 |
|---|
| Index overlap | 39.6% |
|---|
| Active share | 60.4% |
|---|
Top holdings
- Federal Bank Ltd. — 2.9%
- Bharti Hexacom Limited — 2.7%
- AU Small Finance Bank Limited — 2.3%
- Aditya Birla Capital Ltd — 2.3%
- Mankind Pharma Limited — 2.3%
- One 97 Communications Limited — 2.2%
- Prestige Estates Projects Limited — 2.1%
- Eternal Limited — 2.1%
- UNO Minda Limited — 2.0%
- Ipca Laboratories Ltd. — 2.0%
Top sectors
- Banking & Financial — 15.0%
- Automobile — 9.8%
- Pharma & Biotech — 9.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.7% | Q3 | #18 of 31 |
| 2025 | 0.0% | Q3 | #22 of 29 |
| 2024 | 21.0% | Q4 (Bottom) | #25 of 29 |
| 2023 | 20.8% | Q4 (Bottom) | #28 of 28 |
| 2022 | −1.7% | Q4 (Bottom) | #18 of 22 |